{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:40:38Z","timestamp":1792503638459,"version":"4.5.0"},"reference-count":54,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Metagenomic next-generation sequencing (mNGS) enables agnostic detection of bacteria, viruses, fungi, and parasites from clinical specimens. Patient access is restricted due to their current regulatory classification as Laboratory Developed Tests, which are offered by a limited number of laboratories. While patient access may be expanded through Food and Drug Administration authorization of mNGS-based\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      diagnostics, some regulatory requirements for achieving this classification can be challenging to apply due to the agnostic nature of mNGS. For example, existing guidelines recommend organism-by-organism performance characterization similar to targeted molecular tests involving fixed analytes with stable detection thresholds. This minireview synthesizes validation and regulatory challenges unique to mNGS-based diagnostics and describes how laboratories and developers currently navigate available pathways. We focus on core analytical and clinical validation challenges, including discussion on the central role of bioinformatics pipelines and reference databases. We then summarize practical considerations for regulatory engagement, labeling, clinical-facing reporting, and alignment of mNGS assays to existing quality system frameworks. Finally, we outline future oversight considerations, including the need to distinguish mNGS from multiplexed PCR paradigms and the potential value of modular, component-based regulatory approaches that separately evaluate reagents, instruments, software, and databases, enabling system-level oversight rather than organism-by-organism validation. Together, these considerations aim to support risk-appropriate, scalable oversight, and accelerate adoption of mNGS in clinical microbiology.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.00987-26","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:00:27Z","timestamp":1789045227000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["When tests don\u2019t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics"],"prefix":"10.1128","author":[{"given":"Nick P. G.","family":"Gauthier","sequence":"first","affiliation":[{"name":"BugSeq Bioinformatics Inc.","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kapoor","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-5635","authenticated-orcid":true,"given":"David C.","family":"Gaston","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05grhsk96","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt Health","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Prasad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xsjmh40","id-type":"ROR","asserted-by":"publisher"}],"name":"ASM","place":["Washington, DC, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Nwaobia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xsjmh40","id-type":"ROR","asserted-by":"publisher"}],"name":"ASM","place":["Washington, DC, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-8477","authenticated-orcid":true,"given":"Colleen S.","family":"Kraft","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03czfpz43","id-type":"ROR","asserted-by":"publisher"}],"name":"Emory University","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0119-5491","authenticated-orcid":true,"given":"Dev","family":"Mittar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xsjmh40","id-type":"ROR","asserted-by":"publisher"}],"name":"ASM","place":["Washington, DC, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03275-1"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0349-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202305-0901OC"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00612-23"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2026.1802485"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1419"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.68"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01491-15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02007-18"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.837621"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-026-11589-1"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0539-RA"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jaoacint\/qsag085"},{"key":"e_1_3_3_15_2","unstructured":"US Food and Drug Administration. 2021. De novo classification request for biofire respiratory panel 2.1 (RP2.1). DEN200031. Silver Spring MD FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN200031."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01871-22"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00066-22"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.1953"},{"key":"e_1_3_3_19_2","unstructured":"Heger M. 2018. FDA mulls guidelines for NGS-based infectious disease diagnostics. GenomeWeb. Available from: https:\/\/www.genomeweb.com\/sequencing\/fda-mulls-guidelines-ngs-based-infectious-disease-diagnostics. Retrieved 18 Jun 2026."},{"key":"e_1_3_3_20_2","unstructured":"Food and Drug Administration. 2009. Respiratory viral panel multiplex nucleic acid assay - class II special controls guidance for industry and FDA staff. Available from: https:\/\/www.fda.gov\/medical-devices\/guidance-documents-medical-devices-and-radiation-emitting-products\/respiratory-viral-panel-multiplex-nucleic-acid-assay-class-ii-special-controls-guidance-industry-and"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.567572"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2476-x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-020-03038-z"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/mra.01261-23"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jam.14919"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02225"},{"key":"e_1_3_3_27_2","unstructured":"Illumina. 2017. Effects of index misassignment on multiplexing and downstream analysis. Available from: https:\/\/www.illumina.com\/content\/dam\/illumina-marketing\/documents\/products\/whitepapers\/index-hopping-white-paper-770-2017-004.pdf"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","unstructured":"Sinha R Stanley G Gulati GS Ezran C Travaglini KJ Wei E Chan CKF Nabhan AN Su T Morganti RM Conley SD Chaib H Red-Horse K Longaker MT Snyder MP Krasnow MA Weissman IL. 2017. Index switching causes \u201cspreading-of-signal\u201d among multiplexed samples in Illumina HiSeq 4000 DNA sequencing. Molecular Biology. doi:10.1101\/125724","DOI":"10.1101\/125724"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4703-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23563-4"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-4428-5"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-3217-x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr771"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.238170.118"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104812"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30199-7"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0461"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.002809"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2024.1278228"},{"key":"e_1_3_3_40_2","volume-title":"The NCBI Handbook","author":"Pruitt K","year":"2012","unstructured":"Pruitt K, Brown G, Tatusova T, Maglott D. 2012. The reference sequence (RefSeq) database. In McEntyre J, Ostell J (ed), The NCBI Handbook. National center for biotechnology information (US)."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11306-6"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02023-1"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03198-7"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3410\/M3-14"},{"key":"e_1_3_3_45_2","unstructured":"Clinical and Laboratory Standards Institute. 2022. A framework for using CLSI documents to evaluate medical laboratory test methods. (CLSI EP19:2022). Available from: https:\/\/clsi.org\/shop\/standards\/ep19\/"},{"key":"e_1_3_3_46_2","unstructured":"FDA. 2024. Marketing submission recommendations for a predetermined change control plan for artificial intelligence\/machine learning (AI\/ML)-enabled device software functions. Draft Guidance for Industry and Food and Drug Administration Staff. Available from: https:\/\/www.fda.gov\/media\/166704\/download"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00476.2018"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00472-18"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa035"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00605-24"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00727-9"},{"key":"e_1_3_3_52_2","unstructured":"Clinical and Laboratory Standards Institute. 2019. A quality management system model for laboratory services. (CLSI QMS01:2019). Available from: https:\/\/clsi.org\/shop\/standards\/ep19\/"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00074-09"},{"key":"e_1_3_3_54_2","unstructured":"FDA. 2023. Antimicrobial susceptibility test (AST) system devices \u2013 updating breakpoints in device labeling. Draft Guidance for Industry and Food and Drug Administration Staff Draft Guidance. https:\/\/www.fda.gov\/media\/172463\/download."},{"key":"e_1_3_3_55_2","unstructured":"U.S. Food and Drug Administration. 2024. Summary of safety and effectiveness data (SSED): TruSight oncology comprehensive. premarket approval (P230011). U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/P230011B.pdf."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00987-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00987-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:00:25Z","timestamp":1792501225000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00987-26"}},"subtitle":[],"editor":[{"given":"Nathan A.","family":"Ledeboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":54,"alternative-id":["10.1128\/jcm.00987-26"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00987-26","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00987-26"}}